Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04795206 · ClinicalTrials.gov registry record
Natural Disease Progression in Participants With Choroideremia
A clinical trial of Choroideremia, sponsored by Biogen.
- Completed
- Registry status
- 1,178
- Enrollment target
- 1
- Study location
NCT04795206 is a study of Choroideremia that has completed, run by Biogen. The registered enrollment target is 1,178 participants, below the 2,966-participant average among 7 other Choroideremia trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state.
The verdict
NCT04795206, a study of Choroideremia, has completed, sponsored by Biogen.
- COMPLETED
- Registry status
- 1,178 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to quantify disease progression measured by best corrected visual acuity (BCVA) in the real-world setting among Choroideremia (CHM) participants. The secondary objectives are to describe demographic and baseline clinical characteristics among CHM participants and to match CHM participants in the Intelligent Research in Sight (IRIS®) Registry to Biogen's investigator sponsored trial (IST) study population using propensity score matching.
Conditions Studied
Interventions
- OTHER No Intervention
Study Locations (1)
California
- Research Site - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,178 participants |
| Start Date | 2020-08-26 |
| Est. Completion | 2021-08-10 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04795206
The ClinicalTrials.gov registry entry for NCT04795206 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 1,178 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 2,966-participant average among 7 other Choroideremia trials with a reported enrollment target (60% lower). The listed sponsor is Biogen, which has 334 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Choroideremia appearing as the primary indexed condition, and to 1 intervention - of which No Intervention is the first listed.
NCT04795206 reports 1 study location spanning 1 distinct geographic area - top geographies include California.
Frequently Asked Questions
What is clinical trial NCT04795206 about?
NCT04795206 is a clinical study titled "Natural Disease Progression in Participants With Choroideremia". The primary objective of this study is to quantify disease progression measured by best corrected visual acuity (BCVA) in the real-world setting among Choroideremia (CHM) participants. The secondary objectives are to describe demographic and baseline clinical characteristics among CHM participants a...
What is the current status of trial NCT04795206?
This trial is currently completed. The enrollment target is 1,178 participants. The study started on 2020-08-26. Estimated completion is 2021-08-10.
What conditions does trial NCT04795206 study?
This clinical trial studies the following conditions: Choroideremia.
What interventions are being tested in trial NCT04795206?
The interventions under investigation include: No Intervention (OTHER).
Who is sponsoring clinical trial NCT04795206?
This trial is sponsored by Biogen, which has 334 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04795206 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Choroideremia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
High Resolution Retinal Imaging
RECRUITING
-
Inherited Retinal Degenerative Disease Registry
RECRUITING
-
Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration
RECRUITING
-
Dose Escalation Study of Intravitreal 4D-110 in Patients With Choroideremia
ACTIVE NOT RECRUITING · Phase 1
-
Study to Evaluate Safety of RTx-015 Injection in Retinitis Pigmentosa or Choroideremia Patients (ENVISION)
ACTIVE NOT RECRUITING · Phase 1
-
Safety and Dose-escalation Study of AAV2-hCHM in Participants With CHM (Choroideremia) Gene Mutations
COMPLETED · Phase 1
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.